Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260488 | 0.79 | FSCN1 (0.42) | MAPK1MAPTGAACYP3A4TSHR | |
| SCHEMBL24260363 | 0.79 | MLYCD (0.33) | MLYCDALDH1A1 | |
| SCHEMBL20264395 | 0.71 | POLB (0.45) | MAPTGAAMLYCD | |
| SCHEMBL29940563 | 0.71 | POLB (0.45) | MAPTGAAMLYCD | |
| SCHEMBL24481491 | 0.71 | CYP3A4 (0.42) | MAPK1MAPTGAACYP3A4TSHR | |
| SCHEMBL24011586 | 0.70 | SIGMAR1 (0.45) | ALDH1A1 | |
| SCHEMBL18935755 | 0.68 | MLYCD (0.50) | TSHRMLYCDALDH1A1 | |
| SCHEMBL19848536 | 0.68 | CYP3A4 (0.48) | MAPK1MAPTGAACYP3A4TSHR | |
| SCHEMBL10518971 | 0.66 | CYP3A4 (0.41) | MAPK1MAPTGAACYP3A4TSHR | |
| SCHEMBL14156548 | 0.66 | MAPK1 (0.34) | MAPK1MAPTGAACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | MAPK1 2750/4885MAPT 1332/4885GAA 1238/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | MAPK1 3627/4885MAPT 3984/4885GAA 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.